Movatterモバイル変換


[0]ホーム

URL:


SG10201507362TA - Novel Regulatory Proteins And Inhibitors - Google Patents

Novel Regulatory Proteins And Inhibitors

Info

Publication number
SG10201507362TA
SG10201507362TASG10201507362TASG10201507362TASG10201507362TASG 10201507362T ASG10201507362T ASG 10201507362TASG 10201507362T ASG10201507362T ASG 10201507362TASG 10201507362T ASG10201507362T ASG 10201507362TASG 10201507362T ASG10201507362T ASG 10201507362TA
Authority
SG
Singapore
Prior art keywords
inhibitors
regulatory proteins
novel regulatory
novel
proteins
Prior art date
Application number
SG10201507362TA
Inventor
Paul Greengard
Wenjie Lou
Gen He
Peng Li
Lawrence Wennogle
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies IncfiledCriticalIntra Cellular Therapies Inc
Publication of SG10201507362TApublicationCriticalpatent/SG10201507362TA/en

Links

Classifications

Landscapes

SG10201507362TA2009-08-052010-08-05Novel Regulatory Proteins And InhibitorsSG10201507362TA (en)

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
US23146209P2009-08-052009-08-05

Publications (1)

Publication NumberPublication Date
SG10201507362TAtrue SG10201507362TA (en)2015-10-29

Family

ID=43544826

Family Applications (2)

Application NumberTitlePriority DateFiling Date
SG10201507362TASG10201507362TA (en)2009-08-052010-08-05Novel Regulatory Proteins And Inhibitors
SG2012008215ASG178279A1 (en)2009-08-052010-08-05Novel regulatory proteins and inhibitors

Family Applications After (1)

Application NumberTitlePriority DateFiling Date
SG2012008215ASG178279A1 (en)2009-08-052010-08-05Novel regulatory proteins and inhibitors

Country Status (5)

CountryLink
US (1)US9605041B2 (en)
EP (1)EP2461673A4 (en)
JP (2)JP6166534B2 (en)
SG (2)SG10201507362TA (en)
WO (1)WO2011016861A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
WO2010132127A1 (en)2009-05-132010-11-18Intra-Cellular Therapies, Inc.Organic compounds
EP2776035B1 (en)2011-11-012016-08-10Modgene, LlcCompositions and methods for reduction of amyloid-beta load
US9345744B2 (en)2012-04-252016-05-24Musc Foundation For Research DevelopmentPeptide-based collagen modulators for wound healing and tissue repair
WO2014127331A1 (en)2013-02-172014-08-21Intra-Cellular Therapies, Inc.Novel uses
KR102234112B1 (en)*2014-06-272021-04-02한양대학교 산학협력단Brain Specific Nuecleic Acid delivery
US10285992B2 (en)2014-08-072019-05-14Intra-Cellular Therapies, Inc.Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
US10131671B2 (en)2014-08-072018-11-20Intra-Cellular Therapies, Inc.Organic compounds
EP3436083A4 (en)2016-03-282019-11-27Intra-Cellular Therapies, Inc. NEW COMPOSITIONS AND METHODS
JP6994715B2 (en)*2017-10-042022-02-04国立大学法人京都大学 Molecular probe for Bcr-Abl protein imaging
JP7401442B2 (en)2018-01-312023-12-19イントラ-セルラー・セラピーズ・インコーポレイテッド new use

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
JPS6032638B2 (en)1976-09-011985-07-29武田薬品工業株式会社 3-Aminopyrazolo[3,4-d]pyrimidine derivative
EP0063381A1 (en)1981-04-221982-10-27Byk Gulden Lomberg Chemische Fabrik GmbHPyrazolo(3-4-d) pyrimidines, process for their preparation and pharmaceutical compositions containing them
HU186891B (en)1981-06-121985-10-28Richter Gedeon VegyeszetProcess for producing esters of apovincaminic acid
US4666908A (en)1985-04-051987-05-19Warner-Lambert Company5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
US5385915A (en)1990-05-161995-01-31The Rockefeller UniversityTreatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
US5250534A (en)1990-06-201993-10-05Pfizer Inc.Pyrazolopyrimidinone antianginal agents
NZ238609A (en)1990-06-211993-12-23Schering CorpPolycyclic guanine derivatives; preparation, pharmaceutical compositions,
US5272055A (en)1991-12-241993-12-21The University Of Kentucky Research FoundationDetection of Alzheimer's disease and other diseases using a photoaffinity labeling method
US5294612A (en)1992-03-301994-03-15Sterling Winthrop Inc.6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
US5521184A (en)1992-04-031996-05-28Ciba-Geigy CorporationPyrimidine derivatives and processes for the preparation thereof
US20020006963A1 (en)1992-06-232002-01-17Young James W.Method of using and compositions comprising (-) sibutramine optionally in combination with other pharmacologically active compounds
FI953981A0 (en)1993-02-261995-08-24Schering Corp 2-Benzyl-polycyclic guanine derivatives and a process for their preparation
GB9304919D0 (en)1993-03-101993-04-28Celltech LtdChemical compounds
US5543520A (en)1993-10-011996-08-06Ciba-Geigy CorporationPyrimidine derivatives
SK47096A3 (en)1993-10-121996-10-02Du Pont Merck Pharma1n-alkyl-n-arylpyrimidinamines and derivatives thereof
US5620981A (en)1995-05-031997-04-15Warner-Lambert CompanyPyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
IL117923A (en)1995-05-032000-06-01Warner Lambert CoAnti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US5744346A (en)1995-06-071998-04-28Athena Neurosciences, Inc.β-secretase
GB9523675D0 (en)1995-11-201996-01-24Celltech Therapeutics LtdChemical compounds
US5824683A (en)1995-11-281998-10-20Schering Corporation2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones
GB9526245D0 (en)1995-12-211996-02-21Celltech Therapeutics LtdChemical compounds
US5798246A (en)1996-03-251998-08-25Incyte Pharmaceuticals, Inc.Cyclic nucleotide phosphodiesterase
US5777195A (en)1996-05-171998-07-07The Rockefeller UniversityKnockout mutant mouse for DARPP-32 and use thereof
GB9610964D0 (en)1996-05-241996-07-31Pharmacia & Upjohn SpaSubstituted tetralylmethylen-oxindole analogues as tyrosine kinase inhibitors
JPH1143499A (en)1996-09-111999-02-16Takeda Chem Ind LtdNew protein and its dna
US5885834A (en)1996-09-301999-03-23Epstein; Paul M.Antisense oligodeoxynucleotide against phosphodiesterase
GB9622363D0 (en)1996-10-281997-01-08Celltech Therapeutics LtdChemical compounds
JP2001507349A (en)1996-12-232001-06-05セルテック セラピューティックス リミテッド Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
AU742388B2 (en)1996-12-242002-01-03Chugai Seiyaku Kabushiki KaishaAromatic amine derivatives having nos inhibiting action
SE9701398D0 (en)1997-04-151997-04-15Astra Pharma Prod Novel compounds
IT1291372B1 (en)1997-05-211999-01-07Schering Plough S P A USE OF HETEROCYCLIC ANALOGS OF 1,2,4-TRIAZOLE (1,5-C) PYRIMIDINS FOR THE PREPARATION OF MEDICATIONS USEFUL FOR THE TREATMENT OF DISEASES
EP0994860A1 (en)1997-07-032000-04-26Du Pont Pharmaceuticals CompanyAryl-and arylamino-substituted heterocycles as corticotropin releasing hormone antagonists
US6440965B1 (en)1997-10-152002-08-27Krenitsky Pharmaceuticals, Inc.Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
WO1999020273A1 (en)1997-10-171999-04-29The Rockefeller UniversityUse of an inhibitor of the dephosphorylation of darpp-32 for treating schizophrenia
US6013621A (en)1997-10-172000-01-11The Rockfeller UniversityMethod of treating psychosis and/or hyperactivity
GB9722520D0 (en)1997-10-241997-12-24Pfizer LtdCompounds
AU3053999A (en)1998-03-311999-10-25Kyowa Hakko Kogyo Co. Ltd.Nitrogenous heterocyclic compounds
US6133273A (en)1998-05-082000-10-17American Home Products CorporationPyrazolopyrimidine-2,4-dione sulfonamides
PE20000728A1 (en)1998-06-262000-08-21Cocensys Inc HETEROCYCLES 4-BENZYL PIPERIDINE ALKYLSULFOXIDE AND THEIR USE AS SUBTYPE-SELECTIVE NMDA RECEPTOR ANTAGONISTS
JP4403443B2 (en)1998-09-172010-01-27大塚製薬株式会社 LY6H gene
US6699671B1 (en)1998-09-242004-03-02Pharmacia & Upjohn CompanyAlzheimer's disease secretase, APP substrates therefor, and uses therefor
JP2000224992A (en)1998-11-302000-08-15Tanabe Seiyaku Co Ltd Novel phosphodiesterase and its gene
GB9907658D0 (en)1999-04-061999-05-26Zeneca LtdChemical compounds
MXPA02000293A (en)1999-06-252004-05-21Memory Pharmaceutical CorpCyclic amp phosphodiesterase isoforms and methods of use.
CA2376951A1 (en)1999-06-302001-01-04Peter J. SinclairSrc kinase inhibitor compounds
US6498165B1 (en)1999-06-302002-12-24Merck & Co., Inc.Src kinase inhibitor compounds
DE19931206A1 (en)1999-07-072001-01-11Stief ChristianRelaxing, or increasing cyclic adenosine monophosphate concentration in smooth muscular tissue, e.g. by administration of cAMP phosphodiesterase inhibitors, dipyridamole or sildenafil
AU779908B2 (en)1999-09-102005-02-17Merck & Co., Inc.Tyrosine kinase inhibitors
WO2001021219A2 (en)*1999-09-212001-03-29The Government Of The United States Of America, As Represented By The Secretary Of Health And Human ServicesImaging of drug accumulation as a guide to antitumor therapy
CA2379585C (en)1999-09-302006-06-20James W. DarrowCertain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines
US20020147197A1 (en)1999-10-082002-10-10Newman Michael J.Methods and compositions for enhancing pharmaceutical treatments
EA200200240A1 (en)1999-10-112002-10-31Пфайзер Инк. 5- (2-SUBSTITUTED-5-HETEROCYCLILESULPHONYLPYRID-3-IL) -DIGIDROPYRAZOLO [4,3-d] PYRIMIDIN-7-ONE AS PHYSPHODESTERASE INHIBITORS
IL152925A (en)1999-10-212010-04-15PfizerPharmaceutical compositions for treatment of neuropathy comprising an inhibitor of cyclic guanosine 3',5'-monophosphate phosphodiesterase 5 and either gabapentin or pregabalin
AU2005201482A1 (en)1999-11-082005-05-05Pfizer Inc.Compounds for the treatment of female sexual dysfunction
SE9904724D0 (en)1999-12-221999-12-22Carlsson A Research Ab New modulators of dopamine neurotransmission I
WO2001056567A1 (en)2000-02-042001-08-09Novo Nordisk A/S2,4-diaminothiazole derivatives and their use as glycogen synthase kinase-3 (gsk-3) inhibitors
US7087608B2 (en)2000-03-032006-08-08Robert Charles AtkinsUse of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
US6333167B1 (en)2000-03-102001-12-25American Home Products Corp.Methods and reagents for identifying inhibitors of proteolysis of membrane-associated proteins
EP1136485A1 (en)2000-03-232001-09-26Sanofi-SynthelaboAminophenyl pyrimidone derivatives
AU2001249717B2 (en)2000-04-032006-03-30Bristol-Myers Squibb CompanyFluorescence assay for gamma-secretase activity and inhibitors
AU2001257006A1 (en)2000-04-112001-10-23Du Pont Pharmaceuticals CompanySubstituted lactams as inhibitors of abeta protein production
WO2001078721A1 (en)2000-04-132001-10-25Mayo Foundation For Medical Education And ResearchAβ42 LOWERING AGENTS
WO2001078711A2 (en)2000-04-192001-10-25Lilly Icos, Llc.Pde-v inhibitors for treatment of parkinson's disease
US6579689B2 (en)2000-05-112003-06-17Scios Inc.Modulation of γ-secretase activity
MY128449A (en)2000-05-242007-02-28Sugen IncProdrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
US6693099B2 (en)2000-10-172004-02-17The Procter & Gamble CompanySubstituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
SE0102315D0 (en)2001-06-282001-06-28Astrazeneca Ab Compounds
WO2003014321A2 (en)2001-08-102003-02-20The Rockefeller UniversityCompositions and methods for modulation of darpp-32 phosphorylation
DE60226615D1 (en)2001-08-282008-06-26Schering Corp
US20030211040A1 (en)2001-08-312003-11-13Paul GreengardPhosphodiesterase activity and regulation of phosphodiesterase 1B-mediated signaling in brain
US6649908B2 (en)2001-09-202003-11-18Agilent Technologies, Inc.Multiplexing capillary array for atmospheric pressure ionization-mass spectrometry
BR0213817A (en)2001-11-022004-10-19Pfizer Prod Inc Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors
HN2002000317A (en)2001-11-022003-05-21Pfizer PDE9 INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISORDERS
US20030195205A1 (en)2001-11-022003-10-16Pfizer Inc.PDE9 inhibitors for treating cardiovascular disorders
WO2003042216A1 (en)2001-11-092003-05-22Schering CorporationPolycyclic guanine derivative phosphodiesterase v inhibitors
EP1469810A4 (en)2002-01-042009-01-14Univ Rockefeller COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF DISEASES RELATED TO AMYLOID-BETA PEPTIDE
WO2003070174A2 (en)2002-02-152003-08-28Sympore GmbhConjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
EP1476200A4 (en)2002-02-212008-08-13Univ Rockefeller COMPOSITIONS AND METHODS FOR REGULATING CALCIUM DEPENDENT SIGNALING IN THE BRAIN
JP4552650B2 (en)2002-06-282010-09-29日本新薬株式会社 Amide derivatives and pharmaceuticals
GB0215676D0 (en)2002-07-052002-08-14Novartis AgOrganic compounds
SE0203825D0 (en)2002-12-202002-12-20Astrazeneca Ab Novel fused heterocycles and uses thereof
EP1583820A4 (en)*2003-01-142007-07-18Bristol Myers Squibb CoPolynucleotides and polypeptides associated with the nf-kb pathway
US20050048573A1 (en)2003-02-032005-03-03Plexxikon, Inc.PDE5A crystal structure and uses
WO2004087906A1 (en)2003-03-312004-10-14Pfizer Products Inc.Crystal structure of 3',5'-cyclic nucleotide phosphodiesterase 1b (pde1b) and uses thereof
US7153824B2 (en)2003-04-012006-12-26Applied Research Systems Ars Holding N.V.Inhibitors of phosphodiesterases in infertility
JP2006527230A (en)2003-06-132006-11-30ノバルティス アクチエンゲゼルシャフト 2-Aminopyrimidine derivatives as RAF kinase inhibitors
WO2005019258A2 (en)*2003-08-112005-03-03Genentech, Inc.Compositions and methods for the treatment of immune related diseases
GB0325031D0 (en)2003-10-272003-12-03Novartis AgOrganic compounds
EP2260849A1 (en)2004-01-212010-12-15Emory UniversityCompositions and methods of use for tyrosine kinase inhibitors to treat pathogenic infection
JP5084725B2 (en)2005-06-062012-11-28武田薬品工業株式会社 Organic compounds
GB0512091D0 (en)*2005-06-142005-07-20Novartis AgOrganic compounds
WO2007025103A2 (en)2005-08-232007-03-01Intra-Cellular Therapies, Inc.Organic compounds for treating reduced dopamine receptor signalling activity
JP5453086B2 (en)2006-06-062014-03-26イントラ−セルラー・セラピーズ・インコーポレイテッド Organic compounds
WO2008055959A1 (en)2006-11-092008-05-15Galapagos N.V.Novel compounds useful for the treatment of degenerative & inflammatory diseases
WO2008057599A2 (en)2006-11-102008-05-15Intra-Cellular Therapies, Inc.Methods for the treatment of abeta related disorders and compositions therefor
ES2411604T3 (en)2006-11-132013-07-05Intra-Cellular Therapies, Inc. Organic compounds
US9006258B2 (en)2006-12-052015-04-14Intra-Cellular Therapies, Inc.Method of treating female sexual dysfunction with a PDE1 inhibitor
JP5559043B2 (en)2007-06-072014-07-23イントラ−セルラー・セラピーズ・インコーポレイテッド Novel heterocyclic compounds and uses thereof
WO2008153959A1 (en)2007-06-072008-12-18Intra-Cellular Therapies, Inc.Novel heterocycle compounds and uses thereof
ES2588238T3 (en)2007-12-062016-10-31Intra-Cellular Therapies, Inc. Derivatives of pyrazolopyrimidin-4,6-dione and its use as a pharmaceutical product
CN104370918A (en)2007-12-062015-02-25武田药品工业株式会社Organic compounds
WO2010132127A1 (en)2009-05-132010-11-18Intra-Cellular Therapies, Inc.Organic compounds

Also Published As

Publication numberPublication date
SG178279A1 (en)2012-03-29
US9605041B2 (en)2017-03-28
US20130149309A1 (en)2013-06-13
JP2013500741A (en)2013-01-10
EP2461673A2 (en)2012-06-13
JP6166534B2 (en)2017-07-19
JP2016102110A (en)2016-06-02
WO2011016861A2 (en)2011-02-10
WO2011016861A3 (en)2012-08-23
EP2461673A4 (en)2013-08-07

Similar Documents

PublicationPublication DateTitle
PL2406399T3 (en)Mirac proteins
IL222961A0 (en)Novel dna-dinding proteins and uses thereof
IL218678A0 (en)Protein kinase conjugates and inhibitors
EP2387572A4 (en)Protein kinase c inhibitors and uses thereof
ZA201303776B (en)Bromodomain inhibitors and uses thereof
EP2606031A4 (en)Autotaxin inhibitors and uses thereof
IL218778A0 (en)Lysine specific demethylase - 1 inhibitors and their use
SG10201507362TA (en)Novel Regulatory Proteins And Inhibitors
GB201004179D0 (en)Enzyme inhibitors
GB201004178D0 (en)Enzyme inhibitors
SG10201802316VA (en)Protein purification
ZA201107636B (en)Protease inhibitors
IL240134A0 (en)Novel proteins
ZA201109283B (en)Protein
SG10201408577SA (en)Protein display
HK1171913A (en)Novel regulatory proteins and inhibitors
IL214333A0 (en)Carbamoylphosphonates as inhibitors and uses thereof
IL216594A0 (en)Proteasome inhibitors and uses thereof
GB0909384D0 (en)Protein
GB0915927D0 (en)Novel inhibitors
GB0902661D0 (en)Inhibitors
GB0903650D0 (en)Glyoalase inhibitors
GB0902222D0 (en)Protein expression
GB201003936D0 (en)Novel inhibitors
GB201003502D0 (en)Novel inhibitors

[8]ページ先頭

©2009-2025 Movatter.jp